Evidence map›Paper›PMID 36175828›Full record

ArticleThe journal of headache and pain2022

Exploring the neurobiology of the premonitory phase of migraine preclinically - a role for hypothalamic kappa opioid receptors?

Caroline M Kopruszinski, Robson Vizin, Moe Watanabe, Ashley L Martinez, Luiz Henrique Moreira de Souza, David W Dodick, Frank Porreca, Edita Navratilova

Open access · goldAbstract read
In one paragraph

Article in The journal of headache and pain, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Migraine Treatment: Towards New Pharmacological Targets.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Caroline M KopruszinskiDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ, USA.
Robson VizinDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ, USA.
Moe WatanabeDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ, USA.
Ashley L MartinezDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ, USA.
Luiz Henrique Moreira de SouzaDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ, USA.
David W DodickDepartment of Neurology, Mayo Clinic, Phoenix, USA.
Frank PorrecaDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ, USA.
Edita NavratilovaDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ, USA. edita@arizona.edu.
University of Arizona · USMayo Clinic Hospital · USMayo Clinic in Arizona · US

Funding

Pronociceptive and antinociceptive opioid mechanisms in the central nucleus of the amygdalaR01NS109255 · NINDS · UNIVERSITY OF ARIZONA · PI JI, GUANGCHEN, NAVRATILOVA, EDITA · 2019 to 2023
$2.5M
NINDS NIH HHS R01 NS109255
6 · The paper itself

Abstract

backgroundThe migraine premonitory phase is characterized in part by increased thirst, urination and yawning. Imaging studies show that the hypothalamus is activated in the premonitory phase. Stress is a well know migraine initiation factor which was demonstrated to engage dynorphin/kappa opioid receptors (KOR) signaling in several brain regions, including the hypothalamus. This study proposes the exploration of the possible link between hypothalamic KOR and migraine premonitory symptoms in rodent models.

methodsRats were treated systemically with the KOR agonist U-69,593 followed by yawning and urination monitoring. Apomorphine, a dopamine D1/2 agonist, was used as a positive control for yawning behaviors. Urination and water consumption following systemic administration of U-69,593 was also assessed. To examine if KOR activation specifically in the hypothalamus can promote premonitory symptoms, AAV8-hSyn-DIO-hM4Di (Gi-DREADD)-mCherry viral vector was microinjected into the right arcuate nucleus (ARC) of female and male KOR

resultsSystemic administration of U-69,593 increased urination but did not produce yawning in rats. Systemic KOR agonist also increased urination in mice as well as water consumption. Cell specific Gi-DREADD activation (i.e., inhibition through Gi-coupled signaling) of KOR

conclusionOur studies in rodents identified the KOR in a hypothalamic region as a mechanism that promotes behaviors consistent with clinically-observed premonitory symptoms of migraine, including increased thirst and urination but not yawning. Importantly, these behaviors occurred in the absence of pain responses, consistent with the emergence of the premonitory phase before the headache phase. Early intervention for preventive treatment even before the headache phase may be achievable by targeting the hypothalamic KOR.

Indexed as

Migraine DisordersReceptors, Opioid, kappaAnimalsApomorphineDopamineDynorphinsFemaleHeadacheHypothalamusMaleMiceRatsApomorphineDopamineDynorphinsReceptors, Opioid, kappaArcuate nucleusHypothalamusKappa opioid receptors (KOR)Migraine preventionPremonitory phasePremonitory symptoms

Identifiers

PMID36175828
PMCPMC9524131
OpenAlexW4297963076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.